SCHEMBL7121201

SCHEMBL7121201

CCCc1c(OCc2ccccc2)c2cc(Cl)ccc2[nH]c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
MAPT P10636 2/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
CNR1 P21554 2/20 0.46
ADORA1 P30542 1/20 0.46
RAB9A P51151 1/20 0.45
CSF1R P07333 2/20 0.44
ROCK2 O75116 1/20 0.44
MAP4K4 O95819 1/20 0.44
LCK P06239 1/20 0.44
PIM1 P11309 1/20 0.44
RPS6KB1 P23443 1/20 0.44
CDK2 P24941 1/20 0.44
MAPK1 P28482 1/20 0.44
EPHA2 P29317 1/20 0.44
FLT3 P36888 1/20 0.44
FRK P42685 1/20 0.44
CLK2 P49760 1/20 0.44
GSK3A P49840 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7116100 0.81 SIRT1 (0.45) ALDH1A1MAPTMEN1KMT2AADORA1
SCHEMBL7125974 0.80 SIRT1 (0.44) ALDH1A1MAPTMEN1KMT2AADORA1
SCHEMBL7116736 0.78 SIRT1 (0.42) ALDH1A1MAPTMEN1KMT2AADORA1
SCHEMBL7115575 0.77 SIRT1 (0.42) ALDH1A1MAPTMEN1KMT2ACSF1R
SCHEMBL7114302 0.77 SIRT1 (0.44) ALDH1A1MAPTMEN1KMT2ACNR1
SCHEMBL7116744 0.77 SIRT1 (0.46) ALDH1A1MAPTMEN1KMT2AADORA1
SCHEMBL7114914 0.77 SIRT1 (0.46) ALDH1A1MAPTMEN1KMT2AADORA1
SCHEMBL7124010 0.76 SIRT1 (0.45) ALDH1A1MAPTMEN1KMT2AADORA1
SCHEMBL7546795 0.75 CNR1 (0.39) CNR1CSF1R
SCHEMBL7120967 0.75 SIRT1 (0.42) ALDH1A1MAPTMEN1KMT2ACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069271-A1 Quinolone compounds for use in treating viral infections SMITHKLINE BEECHAM CORPORATION 2003-04-10 US claimed
EP-1244629-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2002-10-02 EP claimed
WO-2001046150-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2001-06-28 WO claimed
US-20030069271-A1 Quinolone compounds for use in treating viral infections SMITHKLINE BEECHAM CORPORATION 2003-04-10 US disclosed
EP-1244629-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2002-10-02 EP disclosed
WO-2001046150-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069271-A1 Quinolone compounds for use in treating viral infections IRF3, MAVS, NQO2 ALDH1A1 1742/4885MAPT 2817/4885MEN1 3110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.